Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Recruiting · NCT03681561 · Registry updated 2026-06-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-12 | NCT03681561 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Incyte Corporation | 153 |
| Veronika Bachanova | 1 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Indiana Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | United States | 1 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| University of Illinois Cancer Center | Chicago | United States | 34 |
| University of Iowa Hospitals and Clinics | Iowa City | United States | 99 |
| University of Minnesota | Minneapolis | United States | 325 |
| University of Wisconsin | Madison | United States | 64 |